Alkermes' head of early R&D jumps ship to newly created Harvard role
Alkermes’ head of early development is leaving the biotech for a newly created position as executive director of therapeutic translation at Harvard Medical School.
Mark Namchuk leaves after 5 years as Alkermes’ senior vice president of pharmaceutical and non-clinical development. His departure comes as Alkermes reorients their R&D program after high-profile struggles.
Namchuk’s job will be to lead the recently created Harvard Therapeutics Initiative. The hire is part of Harvard’s increasingly committed foray into biotech, one that includes an Arie Belldegrun-affilaited 36-acre research campus and, with a consortium of collaborators, a blueprinted $50 million gene and cell therapy center.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.